ZA962747B - Novel intermediates and process for the manufacturNovel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and relatede of camptothecin derivatives (CPT-11) and related compounds. compounds. - Google Patents

Novel intermediates and process for the manufacturNovel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and relatede of camptothecin derivatives (CPT-11) and related compounds. compounds.

Info

Publication number: ZA962747B
Authority: ZA; South Africa
Prior art keywords: cpt; intermediates; camptothecin derivatives; compounds; relatede
Prior art date: 1995-04-07

Application number

ZA9602747A

Other languages

English (en)

Inventor

Kevin E Henegar Kevin Henegar

John C Sih John C Sih

Original Assignee

Pharmacia & Upjohn Co Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-07

Filing date

1996-04-04

Publication date

1998-04-06

1996-04-04 Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc

1998-04-06 Publication of ZA962747B publication Critical patent/ZA962747B/xx

Links

238000000034 method Methods 0.000 title abstract 4
150000001875 compounds Chemical class 0.000 title abstract 3
239000000543 intermediate Substances 0.000 title abstract 3
238000004519 manufacturing process Methods 0.000 title abstract 2
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title 2
WSXJPXFVULHYMX-KRWDZBQOSA-N 7-[(1s)-1-hydroxypropyl]-8-methyl-11h-indolizino[1,2-b]quinolin-9-one Chemical compound C1=CC=C2C=C(CN3C4=CC(=C(C3=O)C)[C@@H](O)CC)C4=NC2=C1 WSXJPXFVULHYMX-KRWDZBQOSA-N 0.000 abstract 1
WSXJPXFVULHYMX-UHFFFAOYSA-N S-Mappicine Natural products C1=CC=C2C=C(CN3C4=CC(=C(C3=O)C)C(O)CC)C4=NC2=C1 WSXJPXFVULHYMX-UHFFFAOYSA-N 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
229960004768 irinotecan Drugs 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heat Sensitive Colour Forming Recording (AREA)
Paper (AREA)
Steroid Compounds (AREA)
Lubricants (AREA)

ZA9602747A 1995-04-07 1996-04-04 Novel intermediates and process for the manufacturNovel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and relatede of camptothecin derivatives (CPT-11) and related compounds. compounds. ZA962747B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41964395A	1995-04-07	1995-04-07

Publications (1)

Publication Number	Publication Date
ZA962747B true ZA962747B (en)	1998-04-06

Family

ID=23663114

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9602747A ZA962747B (en)	1995-04-07	1996-04-04	Novel intermediates and process for the manufacturNovel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and relatede of camptothecin derivatives (CPT-11) and related compounds. compounds.

Country Status (25)

Country	Link
US (3)	US6121451A (2)
EP (1)	EP0835257B1 (2)
JP (2)	JP4281075B2 (2)
KR (1)	KR100423627B1 (2)
CN (5)	CN1241926C (2)
AT (1)	ATE224899T1 (2)
AU (1)	AU717179B2 (2)
CA (1)	CA2214793C (2)
CZ (1)	CZ297862B6 (2)
DE (1)	DE69623960T2 (2)
DK (1)	DK0835257T3 (2)
ES (1)	ES2183943T3 (2)
HK (2)	HK1054234B (2)
HU (1)	HUP9801436A3 (2)
IL (1)	IL117684A (2)
MX (1)	MX9707706A (2)
NO (2)	NO320482B1 (2)
NZ (1)	NZ306664A (2)
PL (2)	PL186446B1 (2)
PT (1)	PT835257E (2)
RU (1)	RU2164917C2 (2)
SI (1)	SI0835257T1 (2)
TW (1)	TW438775B (2)
WO (1)	WO1996031513A1 (2)
ZA (1)	ZA962747B (2)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG88737A1 (en) *	1996-10-30	2002-05-21	Tanabe Seiyaku Co	S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
WO2000020405A1 (en) *	1998-10-07	2000-04-13	Mitsubishi Chemical Corporation	Mixtures of optical isomers of 1,2-disubstituted-2,3-epoxypropanes, process for producing the same, pesticides containing the same as the active ingredient and intermediates thereof
FR2794123B1 (fr)	1999-05-28	2001-07-27	Aventis Pharma Sa	Preparation de derives de la camptothecine et de la nothapodytine
CA2385528C (en)	1999-10-01	2013-12-10	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6855294B2 (en) *	2000-11-22	2005-02-15	Resonance, Inc.	Apparatus and methods for efficient generation of chlorine dioxide
TWI245768B (en)	2001-02-21	2005-12-21	Yakult Honsha Kk	Process for synthesizing camptothecin related compound(s)
US6723853B2 (en) *	2001-08-27	2004-04-20	University Of Pittsburgh	Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins
JP3839813B2 (ja) *	2002-04-17	2006-11-01	ファルマシアコーポレイション	カンプトテシン誘導体の調製に有用な化合物
US7151179B2 (en)	2003-05-12	2006-12-19	Scinopharm Taiwan, Ltd.	Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin
CZ299329B6 (cs)	2003-08-26	2008-06-18	Pliva-Lachema A.S.	Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
CN1852740B (zh) *	2003-09-17	2011-05-11	耐科塔医药公司	多支链聚合物的药物前体
US8394365B2 (en)	2003-09-17	2013-03-12	Nektar Therapeutics	Multi-arm polymer prodrugs
CZ299593B6 (cs)	2003-12-16	2008-09-10	Pliva-Lachema A. S.	Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
US20050197355A1 (en) *	2004-03-02	2005-09-08	Henegar Kevin E.	Compounds useful in preparing camptothecin derivatives
US20050267141A1 (en) *	2004-05-28	2005-12-01	Phytogen Life Sciences Inc.	Process to prepare camptothecin derivatives
US20050272757A1 (en) *	2004-06-04	2005-12-08	Phytogen Life Sciences Inc.	Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
WO2006016203A1 (en) *	2004-08-09	2006-02-16	Shilpa Medicare Limited	An improved process for the preparation of irinotecan hydrochloride trihydrate
US20060046993A1 (en) *	2004-09-01	2006-03-02	Pharmacia Italia S.P.A.	Crystalline polymorphic form of irinotecan hydrochloride
ATE446299T1 (de)	2005-02-07	2009-11-15	Fermion Oy	Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
EP1928883B1 (en)	2005-02-08	2013-10-30	Fermion Oy	Process for the preparation of irinotecan hydrochloride
ES2430375T3 (es)	2005-02-08	2013-11-20	Fermion Oy	Procedimiento para la producción de cloruro de [1,4']bipiperidinil-1'-carbonilo o su clorhidrato
TWI375678B (en) *	2005-06-09	2012-11-01	Yakult Honsha Kk	A method of preparation of a tricyclic ketone
EP1803725A1 (en) *	2005-12-13	2007-07-04	W.C. Heraeus GmbH	Methods for preparing irinotecan
US7462627B2 (en) *	2006-02-09	2008-12-09	Enzon Pharmaceuticals, Inc.	Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) *	2006-02-09	2010-03-02	Enzon Pharmaceuticals, Inc.	Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
WO2008066902A2 (en)	2006-11-30	2008-06-05	Nektar Therapeutics Al, Corporation	Method for preparing a polymer conjugate
KR20090108082A (ko) *	2007-02-09	2009-10-14	엔존 파마슈티컬즈, 인코포레이티드	7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
EP2664632A1 (en) *	2008-07-31	2013-11-20	The Lubrizol Corporation	Novel copolymers and lubricating compositions thereof
US8637466B2 (en)	2008-08-11	2014-01-28	Nektar Therapeutics	Multi-arm polymeric alkanoate conjugates
WO2010025337A1 (en) *	2008-08-29	2010-03-04	Enzon Pharmaceuticals, Inc.	Method of treating ras associated cancer
JP2012503602A (ja)	2008-09-23	2012-02-09	ネクターセラピューティックス	対象において持続的治療薬濃度を実現するための組成物及び方法
US20100098654A1 (en) *	2008-10-21	2010-04-22	Fabio Pastorino	Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
WO2012032531A1 (en) *	2010-09-06	2012-03-15	Avra Laboratories Pvt. Ltd.	Process for the manufacture of irinotecan hydrochloride by total synthesis
US10894087B2 (en)	2010-12-22	2021-01-19	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en)	2010-12-22	2013-12-12	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of taxane-based compounds
JO3283B1 (ar)	2011-04-26	2018-09-16	Sanofi Sa	تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2016008975A1 (en)	2014-07-18	2016-01-21	Sanofi	Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
EP3371192B1 (en)	2015-10-27	2020-06-03	California Pacific Medical Center	Podophyllotoxin derivatives and their use
US10087194B2 (en) *	2015-10-27	2018-10-02	California Pacific Medical Center	Podophyllotoxin derivatives and their use
ES3057783T3 (en)	2016-03-15	2026-03-04	Oryzon Genomics Sa	Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CN105965710B (zh) *	2016-06-28	2019-03-22	常州大学	一种硅棒金钢线切割树脂板的制备方法及应用
US11434196B2 (en)	2019-01-15	2022-09-06	Laurus Labs Limited	Process for preparation of 2-Amino-5-hydroxy propiophenone
CN112300184B (zh) *	2019-08-02	2022-12-06	华东师范大学	一种三元环化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5217499A (en) *	1975-07-31	1977-02-09	Nippon Chemiphar Co Ltd	Preparation of mappicine
DE3682874D1 (de) *	1985-10-21	1992-01-23	Daiichi Seiyaku Co	Pyranoindolizinderivate und verfahren zu ihrer herstellung.
US4981968A (en) *	1987-03-31	1991-01-01	Research Triangle Institute	Synthesis of camptothecin and analogs thereof
US5053512A (en) *	1987-04-14	1991-10-01	Research Triangle Institute	Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US4894456A (en) *	1987-03-31	1990-01-16	Research Triangle Institute	Synthesis of camptothecin and analogs thereof
US5883255A (en) *	1990-10-31	1999-03-16	Smithkline Beecham Corporation	Substituted indolizino 1,2-b!quinolinones
US5405963A (en) *	1993-06-10	1995-04-11	Smithkline Beecham Corporation	Process for asymmetric total synthesis of camptothecin analogues
GB9316352D0 (en) *	1993-08-06	1993-09-22	Erba Carlo Spa	Process for the preparation of 9-amino camptothecin
GB9319944D0 (en) *	1993-09-28	1993-11-17	Erba Carlo Spa	Process for the preparation of 9-amino camptothecin

1996
- 1996-03-27 TW TW085103680A patent/TW438775B/zh not_active IP Right Cessation
- 1996-03-27 IL IL11768496A patent/IL117684A/en not_active IP Right Cessation
- 1996-04-01 ES ES96912468T patent/ES2183943T3/es not_active Expired - Lifetime
- 1996-04-01 US US09/230,245 patent/US6121451A/en not_active Expired - Fee Related
- 1996-04-01 AU AU55278/96A patent/AU717179B2/en not_active Ceased
- 1996-04-01 NZ NZ306664A patent/NZ306664A/xx not_active IP Right Cessation
- 1996-04-01 SI SI9630551T patent/SI0835257T1/xx unknown
- 1996-04-01 HU HU9801436A patent/HUP9801436A3/hu unknown
- 1996-04-01 CA CA002214793A patent/CA2214793C/en not_active Expired - Fee Related
- 1996-04-01 EP EP96912468A patent/EP0835257B1/en not_active Expired - Lifetime
- 1996-04-01 PL PL96322651A patent/PL186446B1/pl not_active IP Right Cessation
- 1996-04-01 CN CNB031030998A patent/CN1241926C/zh not_active Expired - Fee Related
- 1996-04-01 RU RU97118673/04A patent/RU2164917C2/ru not_active IP Right Cessation
- 1996-04-01 DE DE69623960T patent/DE69623960T2/de not_active Expired - Lifetime
- 1996-04-01 CN CNB031030971A patent/CN100396682C/zh not_active Expired - Fee Related
- 1996-04-01 PT PT96912468T patent/PT835257E/pt unknown
- 1996-04-01 JP JP53035696A patent/JP4281075B2/ja not_active Expired - Fee Related
- 1996-04-01 WO PCT/US1996/004163 patent/WO1996031513A1/en not_active Ceased
- 1996-04-01 CN CN03103098XA patent/CN1434043B/zh not_active Expired - Fee Related
- 1996-04-01 CN CNB031031005A patent/CN100537538C/zh not_active Expired - Fee Related
- 1996-04-01 CN CN96193138A patent/CN1100058C/zh not_active Expired - Fee Related
- 1996-04-01 KR KR1019970707091A patent/KR100423627B1/ko not_active Expired - Fee Related
- 1996-04-01 PL PL96355318A patent/PL186564B1/pl not_active IP Right Cessation
- 1996-04-01 DK DK96912468T patent/DK0835257T3/da active
- 1996-04-01 MX MX9707706A patent/MX9707706A/es not_active IP Right Cessation
- 1996-04-01 CZ CZ0311097A patent/CZ297862B6/cs not_active IP Right Cessation
- 1996-04-01 AT AT96912468T patent/ATE224899T1/de active
- 1996-04-04 ZA ZA9602747A patent/ZA962747B/xx unknown
1997
- 1997-10-06 NO NO19974608A patent/NO320482B1/no not_active IP Right Cessation
2000
- 2000-02-22 US US09/511,006 patent/US6235907B1/en not_active Expired - Fee Related
- 2000-10-13 US US09/687,227 patent/US6444820B1/en not_active Expired - Fee Related
2003
- 2003-09-11 HK HK03106488.3A patent/HK1054234B/zh not_active IP Right Cessation
- 2003-09-11 HK HK03106509.8A patent/HK1054236B/zh not_active IP Right Cessation
2005
- 2005-01-25 NO NO20050408A patent/NO329776B1/no not_active IP Right Cessation
2007
- 2007-10-25 JP JP2007277903A patent/JP2008069170A/ja active Pending

Also Published As

Publication number	Publication date
CN100537538C (zh)	2009-09-09
CN1241926C (zh)	2006-02-15
AU717179B2 (en)	2000-03-16
CN1181083A (zh)	1998-05-06
NO20050408L (no)	1997-12-08
IL117684A (en)	2002-02-10
PT835257E (pt)	2003-01-31
DK0835257T3 (da)	2003-02-03
US6444820B1 (en)	2002-09-03
CN1434046A (zh)	2003-08-06
ES2183943T3 (es)	2003-04-01
CA2214793C (en)	2009-10-20
CN1434043B (zh)	2010-04-28
CZ311097A3 (cs)	1998-03-18
HK1054236B (zh)	2010-02-05
HUP9801436A2 (hu)	1998-10-28
CN1434037A (zh)	2003-08-06
PL322651A1 (en)	1998-02-16
ATE224899T1 (de)	2002-10-15
SI0835257T1 (en)	2003-04-30
PL186564B1 (pl)	2004-01-30
HK1054236A1 (zh)	2003-11-21
NO974608D0 (no)	1997-10-06
DE69623960D1 (de)	2002-10-31
CN1434043A (zh)	2003-08-06
IL117684A0 (en)	1996-07-23
WO1996031513A1 (en)	1996-10-10
HK1054234A1 (zh)	2003-11-21
NO974608L (no)	1997-12-08
NZ306664A (en)	1999-11-29
NO329776B1 (no)	2010-12-13
NO320482B1 (no)	2005-12-12
US6235907B1 (en)	2001-05-22
DE69623960T2 (de)	2003-06-05
CN100396682C (zh)	2008-06-25
AU5527896A (en)	1996-10-23
TW438775B (en)	2001-06-07
JP2008069170A (ja)	2008-03-27
PL186446B1 (pl)	2004-01-30
KR19980703691A (ko)	1998-12-05
KR100423627B1 (ko)	2004-07-27
HK1009448A1 (en)	1999-09-10
EP0835257B1 (en)	2002-09-25
CA2214793A1 (en)	1996-10-10
CN1100058C (zh)	2003-01-29
US6121451A (en)	2000-09-19
HK1054234B (zh)	2010-12-24
MX9707706A (es)	1997-12-31
CN1434044A (zh)	2003-08-06
HK1055118A1 (zh)	2003-12-24
HK1055119A1 (en)	2003-12-24
CZ297862B6 (cs)	2007-04-18
HUP9801436A3 (en)	1998-11-30
JP4281075B2 (ja)	2009-06-17
JPH11503156A (ja)	1999-03-23
EP0835257A1 (en)	1998-04-15
RU2164917C2 (ru)	2001-04-10

Publication	Publication Date	Title
IL117684A0 (en)	1996-07-23	Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
IL140419A0 (en)	2002-02-10	Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
ZA961074B (en)	1997-02-26	Chiral Methylphenyloxazolidinones.
BG105009A (en)	2001-11-30	Method for producing 4-carboxyamino-2-substituted 1,2,3,4-tetrahydroquinoline
UA66792C2 (uk)	2004-06-15	Спосіб отримання 2-арил-3-арил-5-галогенпіридинів, що використовуються як інгібітори сох-2 (варіанти)
UA35607C2 (uk)	2001-04-16	Похідні оксазолідинонкарбонової кислоти, спосіб їх одержання, фармацевтична композиція і спосіб її одержання
PL326869A1 (en)	1998-10-26	Method of obtaining derivatives of campyhotecin
IL115627A (en)	2000-02-29	Substituted 3-aminobenzonitriles and their preparation
YU12000A (sh)	2002-11-15	Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
IL146811A0 (en)	2002-07-25	Novel method for preparing benzoperhydroisoindole compounds
HUT52698A (en)	1990-08-28	Process for producing pharmaceutical compositions for treating autoimmune leucoencephalomyelitis like diseases as sclerosis multiplex
NZ320522A (en)	1999-03-29	Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
CZ20011915A3 (cs)	2001-09-12	Způsob výroby cyklenu
ATE234288T1 (de)	2003-03-15	Verfahren zur herstellung eines buthylthuio- isochinolinderivates und zwischenprodukte dafür
GR3031544T3 (en)	2000-01-31	New derivatives of pyridine or pyridazine, process for production thereof and medicaments containing these compounds
ATE188694T1 (de)	2000-01-15	Verfahren zur herstellung von benzopyranderivaten
MY112472A (en)	2001-06-30	Production of nitrosamine-free silicone articles
YU71400A (sh)	2003-04-30	Poboljšani postupak za pripremanje farmaceutski dragocenih derivata norbenzomorfana